Jett Foundation Launches Capital Campaign for Jett’s Place, a Sanctuary for Duchenne Muscular Dystrophy Community

Jett Foundation announces a $10.7 million capital campaign to build Jett’s Place, a first-of-its-kind wellness and retreat center for individuals and families affected by Duchenne muscular dystrophy, with initial $1 million donations from the Emilson Family and ITF Therapeutics.

SA Metrowire Staff
Healthcare
Jett Foundation Launches Capital Campaign for Jett’s Place, a Sanctuary for Duchenne Muscular Dystrophy Community

Jett Foundation announced the launch of a capital campaign to fund the construction of Jett’s Place, a premier wellness and retreat center serving as a sanctuary for individuals and families affected by Duchenne muscular dystrophy (DMD). The fundraising campaign was anchored by two transformative $1 million donations from the Emilson Family and ITF Therapeutics.

Located on a 10-acre campus in Norwell, Massachusetts, Jett’s Place will serve as Jett Foundation’s national headquarters and provide barrier-free accessibility, specialized wellness care, adaptive nature and recreation, and educational programs designed with input from Duchenne families. The campaign has a goal of $10.7 million and has already raised over $5 million during its quiet phase.

Duchenne muscular dystrophy is a progressive neuromuscular disorder diagnosed during childhood that causes loss of motor, pulmonary, and cardiac function, leading to premature death. It affects every 1 in 5,000 live male births and some females, with no cure currently available. Children with Duchenne typically lose their ability to walk around age 12 and succumb to the disease in their early to mid-twenties.

Since 2001, Jett Foundation, headquartered in Norwell, Mass., has worked to empower people and families impacted by Duchenne through transformative programming, educational opportunities, and ongoing support. The foundation is a registered 501(c)(3) charity, and more information can be found at www.jettfoundation.org.

ITF Therapeutics, the U.S. affiliate of Italfarmaco Group, was established in January 2024 to develop and commercialize treatments for rare diseases. The company focuses on learning directly from advocates, researchers, clinicians, and families to design innovative solutions. More information is available at www.itftherapeutics.com.

The capital campaign for Jett’s Place represents a significant milestone for the Duchenne community, offering a dedicated space for wellness and support. With over $5 million already raised, Jett Foundation invites broader community support to bring this project to life.

Blockchain Registration

QR Code for Blockchain Registration